DCM
APTO

DAFNA Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

DAFNA Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-43
Closed -$83K – 84
2015
Q3 		$83K Sell
43
-113
-72% -$251K 0.08% 82
2015
Q2 		$359K Buy
156
+106
+212% +$277K 0.3% 58
2015
Q1 		$121K Buy
+50
New +$121K 0.09% 65

Other funds holding APTO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

DAFNA Capital Management's APTO Position: Q4 2015 in Review

DAFNA Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q4 2015, closing a stake of 43 shares — an estimated $83K sold.

DAFNA Capital Management first reported a position in APTO in Q1 2015 and held it in 3 quarters. The position peaked at $359K in Q2 2015. 11 funds tracked by Wall St. Rank hold APTO as of Q4 2015.

  • DAFNA Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 43 Aptose Biosciences, Inc. shares in Q4 2015, an estimated $83K.
  • DAFNA Capital Management first reported a position in Aptose Biosciences, Inc. in Q1 2015 and held it in 3 quarters.
  • DAFNA Capital Management's Aptose Biosciences, Inc. position peaked at $359K in Q2 2015.
  • 11 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2015.

Based on DAFNA Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.